Bitget App
Trade smarter
Buy cryptoMarketsTradeFuturesEarnSquareMore

News

Stay up to date on the latest crypto trends with our expert, in-depth coverage.

banner
All
Crypto
Stocks
Commodities & Forex
Macro
Fake TikTok Clones Are Running Dangerous Crypto Scams
Fake TikTok Clones Are Running Dangerous Crypto Scams

A new crypto scam is on the rise as hackers target TikTok users through fake clone apps. These fraudulent apps use deepfakes, AI-generated content, and phishing techniques to steal users' crypto wallet seed phrases. The malware, known as SparkKitty, is a recent creation that makes this scam even more dangerous. Stay informed on how to protect your personal information from this growing threat.

BeInCrypto·2025/08/07 12:58
Technical Indicators Align for Solana as Bulls Target $180 Barrier Next
Technical Indicators Align for Solana as Bulls Target $180 Barrier Next

Solana has gained nearly 10% in the past few days, with bulls showing signs of reclaiming control. Positive technical indicators, including a rising RSI and BoP, support the rally — but SOL now faces a crucial resistance level at $176.33 that will determine whether further gains are possible.

BeInCrypto·2025/08/07 12:30
HBAR Whales Accumulate Over 60 Million Tokens: Why the Price Still Isn’t Responding
HBAR Whales Accumulate Over 60 Million Tokens: Why the Price Still Isn’t Responding

Hedera’s HBAR token is up nearly 2% today, but the broader trend still looks shaky. Over the past week, HBAR has dropped close to 10%, and its overall structure continues to raise questions. Despite the Layer 1 network, designed for enterprise-grade applications, showing clear bullish patterns and heavy whale accumulation, the price hasn’t managed a &hellip; <a href="https://beincrypto.com/hbar-price-breakout-delay-whale-buying/">Continued</a>

BeInCrypto·2025/08/07 11:00
Ethereum’s $4,000 Breakout is Just a Matter of Time: 3 Signals Hint the Wait’s Almost Over
Ethereum’s $4,000 Breakout is Just a Matter of Time: 3 Signals Hint the Wait’s Almost Over

Ethereum price is inching toward $4,000, and this time, it might finally break through. With short-term buyers returning, SOPR falling, and resistance fading, the charts and on-chain metrics point to a breakout that’s just a matter of time.

BeInCrypto·2025/08/07 09:30
SEC Internal Disagreements Could be Bad News for Crypto ETFs
SEC Internal Disagreements Could be Bad News for Crypto ETFs

Caroline Crenshaw's dissent at the SEC has caused delays in crypto ETF approvals, leading to a slower timetable for the crypto community's hopes of expanding ETF options.

BeInCrypto·2025/08/07 08:51
Hong Kong's First RWA Industry Whitepaper Released: The Notion of Everything Being RWA is a False Proposition
Hong Kong's First RWA Industry Whitepaper Released: The Notion of Everything Being RWA is a False Proposition

Hong Kong Releases RWA Report, Proposing Tokenized Asset Selection Criteria and Industrialization Path

BlockBeats·2025/08/07 08:44
Flash
12:56
Spot Gold Drops $14 in Short-Term
Spot gold has fallen $14 in the short term, declining over 1.00% during the day, currently reported at $4133.10 per ounce. (Jin Shi)
12:51
Vivos (OTC market code: RDGL) has received Investigational Device Exemption (IDE) approval from the US Food and Drug Administration (FDA) and will initiate a human clinical feasibility study of its Radiogel® Precision Radionuclide Therapy™.
This approval marks a key step forward for the clinical application of this innovative therapy, allowing the company to begin initial safety and feasibility assessments in humans. The Radiogel® technology is designed to enable precise radiation treatment within tumors and is expected to provide a new treatment option for cancer patients. The approved clinical study will collect essential data to lay the foundation for larger-scale clinical trials in the future.
12:51
Anixa Biosciences announced that in its clinical trial of CAR-T cell therapy, no dose-limiting toxicities were observed up to the previously established 3x10⁶/kg dose level.
This positive safety data lays the foundation for further exploration of higher doses and demonstrates the potential of this therapy in terms of patient tolerability.
News